Stephen J. Hankinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stephen J. Hankinson has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Sanjay Divakaran
Brigham and Women’s Hospital
6 shared publications Marcelo F. Di Carli
Cardiovascular Imaging Program, Brigham and Women's Hospital, Boston, MA, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA
3 shared publications- Neal K. Lakdawala
Brigham and Women’s Hospital
3 shared publications Ron Blankstein
Cardiovascular Imaging Program, Brigham and Women's Hospital, Boston, MA, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA
3 shared publications- Jon Hainer
Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School , Boston, MA
2 shared publications - Marcelo Fernando Di Carli
Brigham and Women’s Hospital
2 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 19 (11) , e019970
Impact of 18 FDG-Avidity and Immunosuppression on Idiopathic and Genetic Cardiomyopathies
BACKGROUND: Myocardial 18 fluorodeoxyglucose ( 18 FDG)-avidity is frequently seen in patients with genetic cardiomyopathy, as well as a growing “idiopathic 18 FDG-avidity” group of genotype-negative patients who do not clearly have cardiac sarcoidosis. The prognostic implications of 18 FDG-avidity in patients with and without genetic cardiomyopathy, and the effects of immunosuppression in the latter, remain uncertain. METHODS: This multicenter, retrospective study included all patients who were referred for both 18 FDG-PET and cardiomyopathy genetic testing. Patients with acute myocarditis, biopsy-proven sarcoidosis, or extracardiac 18 FDG-avidity were excluded. We investigated heart failure (HF) composite (left ventricular assist device, heart transplant, HF hospitalization, or death) and arrhythmia composite (sustained ventricular arrhythmias [ventricular tachycardia/ventricular fibrillation], atrioventricular block, or death) outcomes using survival analysis, including Cox proportional hazards modeling and inverse probability of treatment weighting. RESULTS: Among 372 patients, 142 (38%) were 18 FDG-avid. The prevalence of genetic cardiomyopathy among 18 FDG-avid patients (12%) was similar to that of 18 FDG-negative patients (18%; P =0.11). Unadjusted, 18 FDG-avidity was associated with an increased risk of HF composite (hazard ratio, 1.69 [95% CI, 1.04–2.75]; P =0.034) and arrhythmia composite (hazard ratio, 1.63 [95% CI, 1.1–2.4]; P =0.014) outcomes compared with 18 FDG-negative patients. However, these associations were not statistically significant after multivariable adjustment, nor were there significant differences in 18 FDG-associated risks in patients with genetic cardiomyopathy versus genotype-negative patients. After inverse probability of treatment weighting, immunosuppression of 18 FDG-avid patients (n=49) was not associated with a reduction in HF or arrhythmia composite outcomes compared with those who were not immunosuppressed (n=93). CONCLUSIONS: Myocardial-only 18 FDG-avidity is not significantly associated with HF or arrhythmia risk in patients who do not clearly have cardiac sarcoidosis (including those with genetic cardiomyopathy). Immunosuppression therapy does not seem to modify the disease course, suggesting that not all myocardial 18 FDG uptake reflects clinically significant inflammation.
- 1 November 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 19 (11) , e019970
Impact of 18 FDG-Avidity and Immunosuppression on Idiopathic and Genetic Cardiomyopathies
BACKGROUND: Myocardial 18 fluorodeoxyglucose ( 18 FDG)-avidity is frequently seen in patients with genetic cardiomyopathy, as well as a growing “idiopathic 18 FDG-avidity” group of genotype-negative patients who do not clearly have cardiac sarcoidosis. The prognostic implications of 18 FDG-avidity in patients with and without genetic cardiomyopathy, and the effects of immunosuppression in the latter, remain uncertain. METHODS: This multicenter, retrospective study included all patients who were referred for both 18 FDG-PET and cardiomyopathy genetic testing. Patients with acute myocarditis, biopsy-proven sarcoidosis, or extracardiac 18 FDG-avidity were excluded. We investigated heart failure (HF) composite (left ventricular assist device, heart transplant, HF hospitalization, or death) and arrhythmia composite (sustained ventricular arrhythmias [ventricular tachycardia/ventricular fibrillation], atrioventricular block, or death) outcomes using survival analysis, including Cox proportional hazards modeling and inverse probability of treatment weighting. RESULTS: Among 372 patients, 142 (38%) were 18 FDG-avid. The prevalence of genetic cardiomyopathy among 18 FDG-avid patients (12%) was similar to that of 18 FDG-negative patients (18%; P =0.11). Unadjusted, 18 FDG-avidity was associated with an increased risk of HF composite (hazard ratio, 1.69 [95% CI, 1.04–2.75]; P =0.034) and arrhythmia composite (hazard ratio, 1.63 [95% CI, 1.1–2.4]; P =0.014) outcomes compared with 18 FDG-negative patients. However, these associations were not statistically significant after multivariable adjustment, nor were there significant differences in 18 FDG-associated risks in patients with genetic cardiomyopathy versus genotype-negative patients. After inverse probability of treatment weighting, immunosuppression of 18 FDG-avid patients (n=49) was not associated with a reduction in HF or arrhythmia composite outcomes compared with those who were not immunosuppressed (n=93). CONCLUSIONS: Myocardial-only 18 FDG-avidity is not significantly associated with HF or arrhythmia risk in patients who do not clearly have cardiac sarcoidosis (including those with genetic cardiomyopathy). Immunosuppression therapy does not seem to modify the disease course, suggesting that not all myocardial 18 FDG uptake reflects clinically significant inflammation.
- 11 July 2026
- Published by Elsevier in Journal of Nuclear Cardiology
- p. 102807
Distinguishing Desmoplakin Cardiomyopathy from Cardiac Sarcoidosis via Cardiac MRI and FDG PET/CT
- 11 July 2026
- Published by Elsevier in Journal of Nuclear Cardiology
- p. 102807
Distinguishing Desmoplakin Cardiomyopathy from Cardiac Sarcoidosis via Cardiac MRI and FDG PET/CT
- Open Access
- 14 March 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (4)
Ventricular tachycardia ablation associated abnormalities on FDG PET/CT in patients with suspected cardiac sarcoidosis
- 14 March 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (4)
Open AccessVentricular tachycardia ablation associated abnormalities on FDG PET/CT in patients with suspected cardiac sarcoidosis
- 4 December 2025
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 57, 102581
Prevalence of lateral wall myocardial fluorodeoxyglucose uptake in patients with left bundle branch block or ventricular pacing referred for sarcoidosis fluorodeoxyglucose positron emission tomography/computed tomography imaging
- 4 December 2025
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 57, 102581
Prevalence of lateral wall myocardial fluorodeoxyglucose uptake in patients with left bundle branch block or ventricular pacing referred for sarcoidosis fluorodeoxyglucose positron emission tomography/computed tomography imaging
- 1 October 2025
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 19 (2) , 288-290
Patterns of Nonspecific Myocardial FDG Uptake in Patients Without Sarcoidosis With Normal CMR
- 1 October 2025
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 19 (2) , 288-290
Patterns of Nonspecific Myocardial FDG Uptake in Patients Without Sarcoidosis With Normal CMR
- 25 September 2025
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 19 (2) , 282-283
The Predictive Accuracy of Aortic Valve Calcium Score in Mediastinal Radiation Therapy Survivors
- 25 September 2025
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 19 (2) , 282-283
The Predictive Accuracy of Aortic Valve Calcium Score in Mediastinal Radiation Therapy Survivors